News

News Releases

Recent news releases

Month Year

Month Year

Investor Alerts

Mar 30, 2026

Apotex announces leadership changes
Mar 25, 2026

Apotex Expands Canadian Ophthalmology Portfolio with Health Canada's Approval of CLOBIVIS™ (Clobetasol Propionate Ophthalmic Suspension, 0.05%)
Feb 5, 2026

Apotex licenses exclusive Canadian rights to testosterone replacement therapy Nebido® from Grünenthal
Oct 23, 2025

Apotex Receives Health Canada Approval for LOQTORZI® -- The First and Only Immuno-Therapy for Recurrent Unresectable or Metastatic Nasopharyngeal Cancer
Oct 7, 2025

Apotex Strengthens Commitment to Women's Health with Exclusive Canadian Rights to "Linzagolix" for Uterine Fibroid Treatment

Show per page